UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT TO REGULATION A
Date of Report (Date of earliest event reported): December 22, 2020
Emerald Health Pharmaceuticals Inc.
(Exact name of issuer as specified in its charter)
Delaware
State or other jurisdiction of incorporation or organization
82-0669961
(I.R.S. Employer Identification No.)
5910 Pacific Center Blvd., Suite 320, San Diego, CA 92121
(Full mailing address of principal executive offices)
(858) 352 - 0622
(Issuer’s telephone number, including area code)
Title of each class of securities issued pursuant to Regulation A: Common Stock
Item 9. Other Events
Related Party Transaction
On December 22, 2020, the Company received written notice of demand from Emerald Health Sciences Inc. (“EHS”), the Company’s majority stockholder, for payment of $750,000 of outstanding principal owed pursuant to the Loan Agreement between EHS, as lender, and the Company, as borrower, dated as of September 1, 2017, as amended on January 26, 2018 and November 15, 2019. The Company made the principal payment to EHS on December 29, 2020.
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | EMERALD HEALTH PHARMACEUTICALS INC., |
| | a Delaware corporation |
| | |
| | By: | /s/ James DeMesa |
| | | James DeMesa |
| | | President and Chief Executive Officer |
Date: December 29, 2020
